RPA656Hu01 10μg Recombinant Diamine Oxidase (DAO) Organism Species: Homo sapiens (Human) *Instruction manual*

FOR IN VITRO USE AND RESEARCH USE ONLY NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

10th Edition (Revised in Jan, 2014)

[PROPERTIES]

Residues: Ala347~Asp466 kDa Tags: N-terminal His-Tag 94 66.2 Accession: P19801 45 Host: E. coli 33 Subcellular Location: Secreted, extracellular 26 space. 20 **Purity:** >95% Endotoxin Level: <1.0EU per 1µg 14.4 (determined by the LAL method). Formulation: Supplied as lyophilized form in PBS, pH7.4, containing 5% sucrose, 0.01% sarcosyl. 15% SDS-PAGE Predicted isoelectric point: 5.8 Predicted Molecular Mass: 15.0kDa Applications: SDS-PAGE; WB; ELISA; IP.

(May be suitable for use in other assays to be determined by the end user.)

[<u>USAGE</u>]

Reconstitute in sterile PBS, pH7.2-pH7.4.

Designed by Cloud-Clone Corp., Assembled by Uscn Life Science Inc. ISO9001:2008; ISO13485:2003 11271 Richmond Avenue Suite H104, Houston, TX 77082, USA | Toll free: 001-888-960-7402 | Fax: 001-832-538-0088 | Http://www.cloud-clone.us | E-mail: mail@cloud-clone.us Export Processing Zone Building F, Wuhan, Hubel 430056, PRC | Toll free: 0086-800-880-0687 | Fax: 0086-27-8425-8551 | Http://www.uscnk.com | E-mail: mail@cloud-clone.us

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

Stability Test: The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.

[SEQUENCES]

The sequence of the target protein is listed below.

AYEV SVQEAVALYG GHTPAGMQTK YLDVGWGLGS VTHELAPGID CPETATFLDT FHYYDADDPV HYPRALCLFE MPTGVPLRRH FNSNFKGGFN FYAGLKGQVL VLRTTSTVYN YDYIWD

[REFERENCES]

- 1. Namikawa T., et al. (2012) Oncology 82:147-152.
- 2. Maintz L., et al. (2011) Allergy 66:893-902.
- 3. Honzawa Y., et al. (2011) Inflamm. Bowel Dis. 17:E23-5.
- 4. Szczepankiewicz A., et al. (2010) Clin Mol Allergy 8:14-14.